Current Report Filing (8-k)
06 März 2023 - 11:01PM
Edgar (US Regulatory)
0001559356
false
0001559356
2023-03-06
2023-03-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 6, 2023 (February 28, 2023)
IMMUNE
THERAPEUTICS, INC. |
(Exact
name of registrant as specified in its charter) |
Florida |
|
000-54933 |
|
59-3226705 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification No.) |
2431
Aloma Ave., Suite 124, Winter Park, Florida |
|
32792 |
(Address
of principal executive offices) |
|
(Zip
Code) |
888-391-9355 |
(Registrant’s
telephone number, including area code) |
|
(Former
name or former address, if changed since last report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None.
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
February 28, 2023, shareholders holding approximately 50.58% of the outstanding common stock of Immune Therapeutics, Inc. (the “Company”)
executed a written consent (the “Written Consent”) in lieu of a special meeting of the shareholders approving an amendment
to the amended and restated articles of incorporation of the Company to change the Company’s name to “Biostax Corp.”
(the “Articles of Amendment”). Pursuant to Rule 14c-2 of the Exchange Act of 1934, as amended, the Articles of Amendment
may not become effective until at least 20 calendar days following the date on which an information statement informing shareholders
of the Written Consent is first mailed to the Company’s shareholders of record.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
March 6, 2023 |
IMMUNE
THERAPEUTICES, INC. |
|
|
|
/s/
Kelly Wilson |
|
Name:
Kelly Wilson |
|
Title:
Principal Executive Officer |
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Immune Therapeutics Inc (PK) (OTCMarkets): 0 Nachrichtenartikel
Weitere Immune Therapeutics, Inc. News-Artikel